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 Clostridium difficile infection (CDI) is one of the most common hospital-acquired infections. It is originated by a gram-positive strict anaerobic rod shaped bacteria, which can induce from 
watery diarrhoea to pseudomembranous colitis and toxic megacolon, becoming recurrent in most cases.  
 
In the United States, during the 2011, caused about 500,000 infections and 15,000 deaths1, achieving a higher mortality rate than the human immunodeficiency virus (HIV).2 
 
His pathogenesis seems to be related to perturbations of the intestinal microbiota, caused mainly by broad spectrum antibiotics altering the balance of microbial populations, allowing the 
pathogen grow and infect.3 It can be contracted by eating vegetative cells or spores. During  the passage through the stomach most viable cells die, but spores persist, germinate in the 
small intestine, and multiply in the colon. The intestinal mucosa promotes the adhesion of C. difficile to the epithelium, where it produces enzymes and A and B toxins, responsible for 
causing severe inflammation, tissue degradation, watery diarrhoea and pseudomembranous colitis.4 
 
As it is difficult to treat and shows high failure rates for antibiotic therapy, there is an increasing interest in finding new promising therapies, as faecal microbiota Transplantation (FMT) and 
Microbial Ecosystem Therapeutics (MET), both aimed to restore the gut microbiota. 
Background 
 
These are two techniques used to restore the normal intestinal 
microbiota composition, both aimed to remove C. difficile 
infection, especially in recurrence cases. 
 
The FMT consists in donating stool from a healthy person to a 
sick one, they were implemented in 1958 as a clinical treatment 
addressed to humans. With the time, have evolved to MET, 
which are microbial communities synthesized in vitro, simulating 
faeces composition, making the practice more reproducible, 
simple and safe.5 
 
 
– FMT and MET are promising techniques, but there is still a lot of work to do: understand how they exactly work, optimize the composition of the infusions, doses, routes of 
administration, study the long-term effects and define the legal issues. 
– There is a tendency to prioritizing the investigation of the MET. Not only for treating CDI, but also other diseases. In the future it might be synthesized different MET aimed at specific 
groups of patients. 13 
– It’s surprising how a natural technique with stool or derived stool products, could work even when antibiotics can’t remove the infection. 
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What are FMT and MET? 
 
They are useful because restore the normal microbiota, while 
antibiotics still cause more damage, promoting recurrent 
infections.  
 
How does microbiota suppress C. difficile?5  
-Competing for the same nutritional niche  
-Producing molecules and bacteriocins with toxigenic activity 
-Interacting indirectly with its lifecycle 
 
It is a simple, safe and effective technique, normally without 
complications. 7 If it occurs, usually is due to the administration 
form and not because of the technique itself. 8 
Why are FMT and MET useful? 
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FMT and MET are considered by the Food and 
Drug Administration (FDA) as drugs with 
biological origin. 
 
In July 2013 FDA accepted FMT as a treatment for 
patients those do not respond to the 
conventional procedure with antibiotics. 
 
In other cases, if someone wants to apply those 
techniques, the responsible must request a new 
investigational drug application, in order to be 
accountable for the practice. 5 
 
Legislation Results and success of the techniques 
    Donor selection 
Questionnaire in orther to 
see if candidates are qualify 
If they are primising, undergo 
blood and faeces tests 
Acceptation or denegation of 
stool 
FMT: There is no need to be related 
with the patients because there is no 
problem of compatibility. Also there 
are faecal banks like Openbiome. 10 
 
MET: Only donor selection in the first 
phase of isolation. There are 
laboratories that produce MET like the 
probiotic RePOOPulate. 11 
Administration 
 
– Lower gastrointestinal tract: colonoscopy or enema. 
– Upper gastrointestinal tract: nasogastric tube, 
nasojejunal tube, esophagogastroduodenoscopy or 
pills. 
 
Each technique has got advantages and disadvantages 
in relation to the rate of success and the risk they pose 
to the patient. The best route should be evaluated in 
each case. 8 
 
Van Nood et al., 2013, evaluated efficacy of FMT 
vs antibiotics. 12 
 
– Vancomicin + bowel lavage: 23% resolution 
– Vancomicin: 31% resolution  
– Bowel lavge + FMT: 81% resolution   
 
Brand et al., 2012, analysed the response to FMT of 77 
patients with recurrent CDI. 7 
 
-The primary cure rate was 91% (resolution of symptoms 
≤90 days after treatment) 
-The secondary cure rate was 98% (after one further course 
of vancomycin with or without repeat FMT) 
 
Petrof et al., 2013, develop a MET called RePOOPulate. Have been tested in two patients, both remained 
symptom-free  after the treatment and restore the normal bowel pattern. 11 
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